Track topics on Twitter Track topics that are important to you
STAINES-UPON-THAMES, United Kingdom, June 29, 2017 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, announced today it will report fiscal 2017 second quarter earnings results for the period of April 1, 2017, to June 30, 2017, on Tuesday, Aug. 8, 2017. A conference call for investors will begin at 8:30 a.m. Eastern Time. The call can be accessed in three ways:
ABOUT MALLINCKRODTMallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and hemostasis products. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.
Investor Relations Coleman N. Lannum, CFASenior Vice President, Investor Strategy and IRO314firstname.lastname@example.org
Daniel J. Speciale, CPADirector, Investor Relations314email@example.com
MediaRhonda SciarraSenior Communications Manager908firstname.lastname@example.org
Meredith FischerChief Public Affairs Officer314email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mallinckrodt-plc-to-report-earnings-results-for-second-quarter-of-fiscal-2017-300481449.html
SOURCE Mallinckrodt plcNEXT ARTICLE
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...
Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...